Drug Profile
Research programme: T-cell therapies - Apollo Therapeutics
Latest Information Update: 28 Mar 2021
Price :
$50
*
At a glance
- Originator Imperial College of Science, Technology and Medicine; University College London; University of Cambridge
- Developer Apollo Therapeutics; University of Cambridge
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Infections
Most Recent Events
- 28 Mar 2021 No recent reports of development identified for research development in Cancer in United Kingdom
- 28 Mar 2021 No recent reports of development identified for research development in Infections in United Kingdom
- 28 Feb 2020 No recent reports of development identified for research development in Autoimmune-disorders in United Kingdom